Insmed Incorporated
US ˙ NasdaqGS ˙ US4576693075

Introduction

This page provides a comprehensive analysis of the known insider trading history of Matthew Pauls. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Matthew Pauls has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SLNO / Soleno Therapeutics, Inc. Director 10,491
US:SVRA / Savara Inc. CHIEF EXECUTIVE OFFICER, Director 1,536,379
US:ZCOR / Zyla Life Sciences Director 0
US:SBBP / Strongbridge Biopharma plc President & CEO, Director 400,000
US:INSM / Insmed Incorporated Chief Commercial Officer 30,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Matthew Pauls. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases INSM / Insmed Incorporated - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INSM / Insmed Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INSM / Insmed Incorporated Insider Trades
Insider Sales INSM / Insmed Incorporated - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INSM / Insmed Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INSM / Insmed Incorporated Insider Trades
Insider Purchases MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INSM / Insmed Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-12-08 SVRA Pauls Matthew 6,500 1.0599 6,500 1.0599 6,889 215 1.8800 5,331 77.38
2021-12-02 SVRA Pauls Matthew 10,000 1.0954 10,000 1.0954 10,954
2021-11-19 SVRA Pauls Matthew 10,000 1.1100 10,000 1.1100 11,100
2021-11-19 SVRA Pauls Matthew 2,150 1.0650 2,150 1.0650 2,290
2021-11-18 SVRA Pauls Matthew 10,000 1.1000 10,000 1.1000 11,000
2021-08-18 SVRA Pauls Matthew 11,900 1.1904 11,900 1.1904 14,166
2021-08-17 SVRA Pauls Matthew 15,000 1.1800 15,000 1.1800 17,700
2021-05-21 SVRA Pauls Matthew 10,000 1.6298 10,000 1.6298 16,298

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF Insider Trades
Insider Sales MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INSM / Insmed Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-12-16 SVRA Pauls Matthew 54,702 3.3057 54,702 3.3057 180,828 162 1.9400 -74,706 -41.31
2023-12-28 SVRA Pauls Matthew 84,000 4.7131 84,000 4.7131 395,900

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF Insider Trades
Insider Purchases SLNO / Soleno Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INSM / Insmed Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SLNO / Soleno Therapeutics, Inc. Insider Trades
Insider Sales SLNO / Soleno Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INSM / Insmed Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-28 SLNO Pauls Matthew 5,937 71.5508 5,937 71.5508 424,797 11 59.0400 -74,277 -17.49

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SLNO / Soleno Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Matthew Pauls as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-09 2025-06-05 4 SLNO SOLENO THERAPEUTICS INC
Common Stock
A - Award 3,991 10,491 61.40
2025-03-31 2025-03-28 4 SLNO SOLENO THERAPEUTICS INC
Common Stock
S - Sale -5,937 6,500 -47.74 71.55 -424,797 465,080
2025-03-31 2025-03-28 4 SLNO SOLENO THERAPEUTICS INC
Common Stock
M - Exercise 5,937 12,437 91.34 4.60 27,310 57,210
2024-12-16 2024-12-16 4 SVRA Savara Inc
Common Stock
S - Sale -54,702 1,536,379 -3.44 3.31 -180,828 5,078,808
2024-12-16 2024-12-13 4 SVRA Savara Inc
Common Stock
F - Taxes -92,593 1,591,081 -5.50 3.21 -297,224 5,107,370
2024-12-16 2024-12-12 4 SVRA Savara Inc
Common Stock
A - Award 400,000 1,683,674 31.16
2024-06-10 2024-06-06 4 SLNO SOLENO THERAPEUTICS INC
Common Stock
A - Award 6,500 6,500
2023-12-29 2023-12-28 4 SVRA Savara Inc
Common Stock
G - Gift -19,000 1,283,674 -1.46
2023-12-29 2023-12-28 4 SVRA Savara Inc
Common Stock
S - Sale -84,000 1,302,674 -6.06 4.71 -395,900 6,139,633
2023-12-15 2023-12-14 4 SVRA Savara Inc
Common Stock
A - Award 450,000 1,386,674 48.04
2023-12-15 2023-12-14 4 SVRA Savara Inc
Common Stock
F - Taxes -109,680 936,674 -10.48 4.45 -488,076 4,168,199
2022-12-15 2022-12-13 4 SVRA Savara Inc
Common Stock
A - Award 325,000 1,046,354 45.05
2022-01-03 2021-12-31 4 SVRA Savara Inc
Common Stock
F - Taxes -62,318 721,354 -7.95 1.24 -77,274 894,479
2021-12-14 2021-12-14 4 SVRA Savara Inc
Stock Option (Right to Buy)
A - Award 350,000 350,000
2021-12-14 2021-12-14 4 SVRA Savara Inc
Common Stock
A - Award 400,000 783,672 104.26
2021-12-08 2021-12-08 4 SVRA Savara Inc
Common Stock
P - Purchase 6,500 383,672 1.72 1.06 6,889 406,654
2021-12-02 2021-12-02 4 SVRA Savara Inc
Common Stock
P - Purchase 10,000 377,172 2.72 1.10 10,954 413,154
2021-11-22 2021-11-19 4 SVRA Savara Inc
Common Stock
P - Purchase 2,150 367,172 0.59 1.06 2,290 391,038
2021-11-22 2021-11-19 4 SVRA Savara Inc
Common Stock
P - Purchase 10,000 365,022 2.82 1.11 11,100 405,174
2021-11-22 2021-11-18 4 SVRA Savara Inc
Common Stock
P - Purchase 10,000 355,022 2.90 1.10 11,000 390,524
2021-08-18 2021-08-18 4 SVRA Savara Inc
Common Stock
P - Purchase 11,900 345,022 3.57 1.19 14,166 410,714
2021-08-18 2021-08-17 4 SVRA Savara Inc
Common Stock
P - Purchase 15,000 333,122 4.72 1.18 17,700 393,084
2021-05-24 2021-05-21 4 SVRA Savara Inc
Common Stock
P - Purchase 10,000 318,122 3.25 1.63 16,298 518,475
2021-04-19 2021-04-19 4 SVRA Savara Inc
Common Stock
P - Purchase X 27,400 308,122 9.76 1.82 49,871 560,813
2021-03-22 2021-03-22 4 SVRA Savara Inc
Common Stock
P - Purchase X 24,100 280,722 9.39 2.07 49,938 581,684
2021-02-23 2021-02-22 4 SVRA Savara Inc
Common Stock
P - Purchase X 28,700 256,622 12.59 1.74 50,038 447,420
2020-12-17 2020-12-16 4 SVRA Savara Inc
Stock Option (Right to Buy)
A - Award 500,000 500,000
2020-09-15 2020-09-15 4 SVRA Savara Inc
Stock Option (Right to Buy)
A - Award 898,639 898,639
2020-09-15 2020-09-15 4 SVRA Savara Inc
Common Stock
A - Award 227,272 227,922 34,964.92
2020-09-15 2017-04-27 4 SVRA Savara Inc
Restricted Stock Units
M - Exercise -650 0 -100.00
2020-09-15 2017-04-27 4 SVRA Savara Inc
Common Stock
M - Exercise 650 650
2020-05-21 2020-05-20 4 ZCOR Zyla Life Sciences
Common Stock
D - Sale to Issuer -26,953 0 -100.00
2020-04-24 2020-04-23 4 ZCOR Zyla Life Sciences
Restricted Stock Units
M - Exercise 6,667 13,333 100.02
2020-04-24 2020-04-23 4 ZCOR Zyla Life Sciences
Common Stock
F - Taxes -952 5,715 -14.28 1.75 -1,666 10,001
2020-04-24 2020-04-23 4 ZCOR Zyla Life Sciences
Common Stock
M - Exercise 6,667 6,667 1.75 11,667 11,667
2020-03-05 2020-03-04 4 ZCOR Zyla Life Sciences
Common Stock
A - Award 13,620 13,620
2019-12-26 2019-12-20 4 SVRA Savara Inc
Stock Option (Right to Buy)
A - Award 12,000 12,000
2019-04-24 2019-04-23 4 ZCOR Egalet Corp
Common Stock
A - Award 20,000 20,000
2019-02-22 2019-02-20 4 SBBP Strongbridge Biopharma plc
Employee Stock Option (right to buy)
A - Award 400,000 400,000
2019-02-22 2019-02-20 4 SBBP Strongbridge Biopharma plc
Ordinary Shares
A - Award 50,000 72,608 221.16
2018-12-14 2018-12-13 4 SVRA Savara Inc
Stock Option (Right to Buy)
A - Award 12,000 12,000
2018-02-28 2018-02-26 4 SBBP Strongbridge Biopharma plc
Ordinary Shares
F - Taxes -17,392 22,608 -43.48 6.60 -114,787 149,213
2018-02-06 2018-02-05 4 SBBP Strongbridge Biopharma plc
Employee Stock Option (right to buy)
A - Award 350,000 350,000
2018-01-02 3 SBBP Strongbridge Biopharma plc
Ordinary Shares
80,000
2018-01-02 3 SBBP Strongbridge Biopharma plc
Ordinary Shares
80,000
2017-05-26 2017-05-25 4 SVRA Savara Inc
Stock Option (Right to Buy)
A - Award 3,750 3,750
2017-01-23 2017-01-23 4 MSTX Mast Therapeutics, Inc.
Restricted Stock Units
A - Award 45,535 45,535
2016-06-17 2016-06-15 4 MSTX Mast Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 79,551 79,551
2015-11-02 2015-10-29 4 MSTX Mast Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 37,794 37,794
2015-11-02 2015-10-29 4 MSTX Mast Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 64,791 64,791
2014-06-04 2014-06-02 4 INSM INSMED INC
Stock Option
A - Award 30,000 30,000 12.58 377,400 377,400
2014-01-14 2014-01-10 4 INSM INSMED INC
Stock Option
A - Award 30,000 30,000 20.49 614,700 614,700
2013-05-28 2013-05-23 4 INSM INSMED INC
Stock Option-Right to Buy
A - Award 25,000 25,000
2013-04-03 2013-04-01 4 INSM INSMED INC
Stock Option-Right to Buy
A - Award 100,000 100,000
2013-04-03 2013-04-01 4 INSM INSMED INC
Stock Option-Right to Buy
A - Award 200,000 200,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)